Incyte acquires Vega Therapeutics for VGA039
Analysis based on 6 articles · First reported Jun 08, 2026 · Last updated Jun 18, 2026
The acquisition of Vega Therapeutics by Incyte is expected to positively impact Incyte's stock price due to the addition of VGA039, a promising Phase 3 asset for von Willebrand disease. This move expands Incyte's hematology portfolio and offers a potential new revenue stream, while also benefiting Star Therapeutics through the significant sale of its subsidiary.
Incyte announced a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront, with potential additional payments of up to $750 million based on sales milestones, totaling up to $2 billion. This acquisition will add VGA039, a novel investigational monoclonal antibody in Phase 3 development for von Willebrand disease, to Incyte's hematology portfolio. VGA039 has received multiple designations from the United States — Food and Drug Administration, including Breakthrough Therapy and Fast Track, and is designed to be the first subcutaneous prophylactic therapy for von Willebrand disease. The transaction has been approved by both companies' boards and is expected to close in the third quarter of 2026, pending regulatory review.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard